OR WAIT null SECS
Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.
The American College of Chest Physicians (CHEST) 2026 Annual Meeting will convene in Phoenix, Arizona, from Sunday, October 18, to Wednesday, October 21, bringing together pulmonary, critical care, and sleep medicine clinicians at the Phoenix Convention Center.¹ The meeting will feature more than 300 educational sessions across 4 days.²
October 18 - 21, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
All on Tuesday, October 20, from 11:14 am to 2:30 pm MST
New data on tozorakimab, mepolizumab, acute exacerbations, and bronchial rheoplasty.
New data on depemokimab, tezepelumab, and dupilumab in pregnancy.
New data infrespacigua, mosliciguat, and TPIP.
This year’s featured topics include artificial intelligence in healthcare and medical education, new guidelines on biologics for severe asthma, therapeutics for advanced COPD, and sleep disorders in critically ill patients.¹ Late-breaking science is concentrated on Tuesday, October 20, with abstracts spanning airway disease, pulmonary vascular disease, sleep, lung cancer, and critical care.
The HCPLive editorial team will be on-site throughout the meeting, providing written coverage of practice-changing data and video interviews with leading pulmonology experts. You can follow HCPLive’s comprehensive CHEST 2026 coverage here. Check out what to expect from this year’s meeting below.
Tuesday, October 20, 11:15 am – 12:15 pm MST
Presenter: Frank C. Sciurba, MD
Tozorakimab is a monoclonal antibody targeting interleukin (IL)-33, an epithelial alarmin involved in COPD pathobiology. This analysis of the replicate phase 3 OBERON and TITANIA trials evaluates patient-reported breathlessness, cough and sputum, and chest symptoms using the Evaluating Respiratory Symptoms in COPD (E-RS:COPD) tool. Participants were current and former smokers with a history of exacerbations who received tozorakimab 300 mg or placebo subcutaneously every 4 weeks for up to 52 weeks.
Presenter: Shiran Shapira, PhD
CD24 is an innate immune checkpoint that attenuates inflammation driven by damage-associated molecular patterns while preserving pathogen-directed immune responses. In this randomized, double-blind, placebo-controlled phase 2b trial, 90 adults with acute respiratory distress syndrome (ARDS) were randomized 2:1 to inhaled, exosome-delivered CD24 or placebo twice daily for 5 days alongside standard of care. The primary endpoint is recovery from hypoxemic respiratory failure at day 7, with 28-day mortality and ventilator-free days among the secondary outcomes.
Tuesday, October 20, 1:45 pm – 2:30 pm MST
Presenter: Michael Lester, MD
Bronchial rheoplasty combines mechanical mucus disimpaction with pulsed electric field airway mucosal remodeling. RheSolve randomized 273 patients with moderate-to-severe chronic bronchitis 2:1 to bronchial rheoplasty or a sham mechanical comparator procedure across 37 centers in the US and Europe. The final analysis reports 24-month COPD Assessment Test and Cough and Sputum Assessment Questionnaire outcomes, along with results from 66 comparator patients who crossed over to active treatment.
Presenter: Gabor Kovacs, MD, PhD, FRCPC
Pulmonary hypertension associated with COPD (PH-COPD) carries reduced functional capacity and increased mortality, and there are currently no approved PH-targeted therapies for this population. INSIGNIA PH-COPD randomized participants 2:1 to frespaciguat (MK-5475), an investigational inhaled soluble guanylate cyclase (sGC) stimulator, at 380 μg once daily or placebo for 24 weeks. The primary endpoint is change in 6-minute walk distance (6MWD) at week 24, with NT-proBNP and WHO functional class as secondary endpoints.
Presenter: George Washko, MD
Mucus plugs are associated with poor outcomes in COPD, and IL-33 has been implicated in mucus dysfunction. This exploratory analysis of the PROSPERO extension, which enrolled patients completing OBERON or TITANIA, uses centrally read CT scans at baseline, week 52, and week 80 to assess whether tozorakimab’s effect on mucus-plugged lung segments persists with longer treatment.
Tuesday, October 20, 1:45 pm – 2:30 pm MST
Presenters: Michael E. Wechsler, MD, MMSc; Geoffrey L. Chupp, MD
Depemokimab is an ultra-long-acting anti-IL-5 biologic dosed twice yearly for type 2 asthma. Two integrated analyses of the phase 3 SWIFT-1/-2 trials and the AGILE open-label extension examine 2 years of continuous treatment. One assesses whether achieving 4-component clinical remission at week 52 is associated with better year 2 outcomes, and the other evaluates whether exacerbation protection in year 1 responders persists into year 2, including in patients with comorbid chronic rhinosinusitis with nasal polyps.
Presenter: Fawad Haroon, MD
This open-label randomized trial across 18 tertiary hospitals assigned adults hospitalized with acute exacerbations of COPD to eosinophil-guided or standard fixed-dose corticosteroids. The guided arm received prednisone 60 mg or 20 mg daily for 5 days based on a blood eosinophil threshold of 300 cells/μL, with discontinuation at day 3 for counts below 100 cells/μL, compared with prednisone 40 mg daily for 5 days. The primary outcome is treatment failure, including escalation to ventilation and hospital readmission.
First author: Christopher Brightling, MD
In SUNRISE, the anti-thymic stromal lymphopoietin (TSLP) antibody tezepelumab reduced the maintenance oral corticosteroid (OCS) dose and improved pre-bronchodilator FEV₁ versus placebo in patients with severe, OCS-dependent asthma. This post hoc analysis evaluates lung function changes at week 28 by baseline blood eosinophil count, fractional exhaled nitric oxide (FeNO), and perennial allergy status.
First author: Hossein A. Ghofrani, MD
Mosliciguat is an investigational once-daily inhaled sGC activator designed to restore cyclic GMP production independent of nitric oxide, a mechanism potentially relevant in the oxidative environment of diseased lung. PHocus randomized adults with PH associated with interstitial lung disease (PH-ILD) 2:1 to mosliciguat titrated to a maximally tolerated dose or placebo for 24 weeks. The primary endpoint is percent change in PVR at week 16 measured by right heart catheterization.
Presenter: Reynold A. Panettieri Jr, MD
Mepolizumab was approved by the FDA in May 2025 as add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype. Using US claims data, this interim analysis characterizes patients who initiated mepolizumab for COPD between May 2025 and January 2026, including comorbidities, prior triple therapy, blood eosinophil counts, OCS use, and exacerbation history.
References
Related Content:
